GlaxoSmithKline shares soar after Unilever bids for its consumer healthcare unit

2 years ago 387

Shares of GlaxoSmithKline surged connected Monday, portion Unilever banal tumbled pursuing a failed $68 cardinal bid by the second to get the pharmaceutical giant’s user healthcare arm.

Driving the FTSE 100 higher and astatine the apical of the Stoxx Europe 600’s gainer’s list, was GlaxoSmithKline GSK, +0.91% GSK, +4.55%, up 5% aft saying Saturday that it has rejected an unsolicited £50 cardinal ($68.4 billion) Unilever UL, +1.14% ULVR, -6.90% connection for the portion down painkiller Advil and Sensodyne toothpaste that it jointly owns with Pfizer PFE, -1.06%. Glaxo, which had been readying to rotation disconnected the unit, said it had received 3 abstracted bids from Unilever, the past coming Dec. 20.

At the apical of the decliner’s list, Unilever shares dropped 6%. The U.K. user goods radical announced Monday that it volition focus connected higher-growth categories such arsenic health, quality and hygiene pursuing a strategical review. That program volition see acquisitions and divesting little maturation brands and businesses, it said.

Some investors are hoping Unilever travel up with a 4th bid. A squad of Berenberg analysts led by James Targett, said it wll astir apt request to summation immoderate caller connection to £55 cardinal to get the woody done. That’s arsenic competing bids from Procter & Gamble PG, +0.96% oregon backstage equity can’t beryllium ruled out, helium said, successful a enactment to clients.

And portion Unliever’s absorption is showing itself arsenic “open to much transformative acquisitions,” questions are present besides raised astir its quality to accelerate maturation with the existent portfolio, helium said. Divesting the nutrient & refreshment portion could money a further bid for the Glaxo arm, but that would mean giving up immoderate of Unilever’s astir charismatic categories, said Targett.

Jefferies analysts besides noted immoderate “indigestion risk” for Glaxo shareholders of immoderate deal.

“The mid-2022E rotation of user is wide viewed arsenic an lawsuit that could crystallize value, hence a merchantability apt dampens near-term appetite to ain the banal astatine a clip erstwhile the pipeline remains a work-in progress,” said a squad led by expert Peter Welford. A merchantability successful the £50 cardinal ballpark would permission absorption with £34 cardinal successful currency for that stake, leaving the institution with £12 cardinal nett cash.

“In mentation this warfare thorax provides ample strategical optionality to rebuild a pipeline and put successful absorption therapeutic areas, but astatine slightest initially we expect galore shareholders would fearfulness a ample acquisition and the hazard of inferior returns,” said the analyst. Jefferies rates GlaxoSmithKline a buy.

Elsewhere, shares of Unliever rival Reckitt Benckiser RKT, +2.60% roseate 1.5%. The healthcare assemblage was rising crossed the board, with shares of Novo Nordisk NVO, -3.25% NOVO.B, +1.23% up 1% and Sanofi SNY, +2.37% SAN, +1.10% rising 1.3%.

Investors were besides absorbing information that showed China’s system expanded by 8.1% successful 2021, but sank to 4% implicit a twelvemonth earlier successful the last 3 months of 2021.

The Stoxx Europe 600 scale SXXP, +0.63% roseate 0.2% to 482, coming disconnected past week’s 1% drop, the 2nd consecutive play diminution to commencement 2022.

The German DAX DAX, +0.40% roseate 0.2%, the French CAC 40 PX1, +0.83% roseate astir 0.4% and the FTSE 100 scale UKX, +0.73% climbed 0.6%. U.S. markets are closed Monday in observance of  in observance of Martin Luther King, Jr. Day.

Read Entire Article